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Abstract
Background: Rheumatoid arthritis (RA) is an autoimmune disease with unknown etiology. Anticitrullinated protein
autoantibody has been documented as a highly specific autoantibody associated with RA. Protein arginine
deiminase type 4 (PAD4) is the enzyme responsible for catalyzing the conversion of peptidylarginine into
peptidylcitrulline. PAD4 is a new therapeutic target for RA treatment. In order to search for inhibitors of PAD4,
structure-based virtual screening was performed using LIDAEUS (Ligand discovery at Edinburgh university).
Potential inhibitors were screened experimentally by inhibition assays.
Results: Twenty two of the top-ranked water-soluble compounds were selected for inhibitory screening against
PAD4. Three compounds showed significant inhibition of PAD4 and their IC50 values were investigated. The
structures of the three compounds show no resemblance with previously discovered PAD4 inhibitors, nor with
existing drugs for RA treatment.
Conclusion: Three compounds were discovered as potential inhibitors of PAD4 by virtual screening. The compounds
are commercially available and can be used as scaffolds to design more potent inhibitors against PAD4.
Background
Rheumatoid arthritis (RA) is an autoimmune disease
characterized by chronic inflammation of the joints and
surrounding tissues. About 0.5-1.0% of the adult popula-
tion is affected by the disease [1]. It is the second most
common type of arthritis which often starts after 40 years
of age and before 60 years of age [2,3]. In common with
multiple sclerosis and type-1 diabetes, RA is an autoim-
mune disease with unknown etiology. The factors leading
to the development of RA remain unknown, although
environmental factors, such as smoking and diet have
been implicated [4]. Autoimmune diseases are caused
when the immune system attacks the body’s own tissues.
For RA, the tissues under attack are the synovial mem-
branes around joints which become swollen, stiff, red and
painful leading to joint destruction and functional
disability.
The first written reference to arthritis, dated 123 AD
described symptoms very similar to what we know now
as rheumatoid arthritis. An ancient Indian text, Caraka
Samhita describes a disease where swollen, painful joints
initially strike the hands and feet, then spreads to the
body, causing loss of appetite, and occasionally fever [5].
In 1800, a French physician, A.J. Landré-Beauvais wrote
the first recognized description of rheumatoid arthritis
[6]. The clinical term ‘rheumatoid arthritis’ was coined by
Alfred Garrod, the London rheumatologist, making the
first reference in medical literature [7].
Many autoantibodies that react against various autoan-
tigens are detectable in the sera of RA patients [8] and
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are useful in diagnosis of the disease. Diagnosis at the
early stage of the disease can prevent irreversible joint
damage, reducing signs and symptoms of erosion and
improving physical function [9]. Historically, rheumatoid
factor is an important serological marker for the diagno-
sis of RA and is still used as one of the criteria for the
classification of the disease [1]. It can be found in most
of the RA patients, but it is not a specific marker for RA.
It can also be seen in other bacterial, viral, parasitic dis-
eases and other inflammatory conditions [1]. For disease
diagnosis, it is a good but not ideal marker for RA and
better markers are needed.
Anticitrullinated protein autoantibody (ACPA) has been
documented as a highly specific marker for RA and has
diagnostic and prognostic potential. Several studies have
proven the diagnostic value of RA [10-12]. ACPA can be
detected at the early phases of the disease, even before the
onset of symptoms. Post-translational conversion of an
arginine residue generates peptidylcitrulline (Figure 1)
which is recognized by ACPA. The process is called citrul-
lination or deimination. It is catalyzed by a calcium bind-
ing enzyme called protein arginine deiminase type 4
(PAD4).
Studies have been performed by several research groups
to explore the connection of PAD4 with the disease based
on ethnicity. Polymorphism in PADI4, the gene encoding
PAD4, is found to be associated with RA. Studies show
that the gene is associated with RA susceptibility in Asians
including Koreans, Japanese, and Chinese [13-15]. Most of
the studies demonstrated the association of PADI4 with
RA among Asian populations but not the Caucasian popu-
lation [16]. In a study carried out by Iwamoto et al. [17],
they found a positive association between PADI4 and RA
in population of European descent. Chang et al., [18]
showed that the expression of PADI4 in the synovial fluid
of RA patients is higher than patients of another two types
of arthritis, osteoarthritis and ankylosing spondylitis.
To date, there is no known cure for RA. Current avail-
able treatments are mainly focused on pain relief.
Current treatments available for RA can be classified into
three groups: non-steroidal anti-inflammatory drugs
(NSAIDs), corticosteroids, and disease modifying anti-
rheumatic drugs (DMARDs) [19]. The most common
and useful DMARD is methotrexate (MTX). It is the pre-
ferred drug for current RA treatment but causes side
effects such as nausea, mouth ulcers and hair loss. With
hope of curing the disease, PAD4 has become the new
therapeutic target for RA. PAD4 catalyzes the citrullina-
tion process which generates the epitope for RA. By inhi-
biting the activity of PAD4 it should be possible to
control the development of RA.
With the discovery of PAD4 as a promising target for
the treatment of RA, structure-based drug design can be
carried out to search for new potential drug leads [20].
The cost of the process is relatively low, not requiring
high initial outlays or complex synthesis efforts [20]. In
this research, inhibitors of PAD4 were searched for using
a high-throughput virtual screening program - LIDAEUS
(ligand discovery at Edinburgh university) [21]. This pro-
gram screened approximately 1 million commercially
available compounds against the active site of PAD4.
Potential compounds were then screened experimentally
using an enzyme inhibition assay. From computer-aided
virtual screening, a number of compounds were identified
as weak inhibitors of the enzyme, PAD4.
Results
Expression and purification of PAD4
The majority of the protein expressed by the E. coli system
was in inclusion bodies [22]. There are 18 cysteines in
PAD4 that cause the correct folding of the enzyme, this
presented difficulties as random disulfide bonds formation
between cysteins induces incorrect protein folding and
aggregation, often producing insoluble and inactive
Figure 1 Post-translational conversion of peptidylarginine into peptidylcitrulline catalyzed by protein arginine deminase (PAD) in the
presence of Ca2+.
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protein. Therefore, the medium used for PAD4 expression
was altered in order to produce properly folded protein.
Studier media [23], which provides milder conditions for
protein expression without the use of IPTG yielded more
soluble protein compared to the conventional protein
expression system. PAD4 consists of 663 amino acids and
the theoretical molecular weight of the enzyme is 74.1
kDa. The PAD4 expressed from the system was attached
with Trx-His-S-tags. The molecular weight of the tagged
PAD4 was approximately 91 kDa as shown by SDS-PAGE
analysis. The purity of the obtained enzyme was high,
approximately 90% after one step of purification, with
recovery of 79% activity. About 3 mg of PAD4 was isolated
from 100 ml of culture after purification. The enzymatic
activity of purified PAD4 was determined by citrulline col-
orimetric assay and the protein content was checked
by Bradford protein assay. One unit of PAD4 was defined
as the amount of PAD4 needed to produce 1 μM of
Na-benzoylcitrulline ethyl ester from N-a-benzoylarginine
ethyl ester (BAEE) per hour [24].
High-throughput virtual screening using LIDAEUS
LIDAEUS was utilized to search for inhibitors of PAD4.
LIDAEUS searched for inhibitors using a structure-based
approach. Sitepoints and energy maps were generated
and used to fit and score around 1 million commercially
available small molecules into the active site of PAD4.
The top 500 compounds obtained after docking by
LIDAEUS were extracted and re-docked with the more
exhaustive docking software AutoDock [25].
Initially LIDAEUS performed the docking using a
course-grained approach that is essentially rigid body
docking (rigid protein and rigid ligand) [26], which
enables the screening of large datasets. To get around the
rigid-rigid limitation, LIDAEUS docks the small mole-
cules into the active site using multiple pre-generated
conformations (number determined by the flexibility of
the molecule). After LIDAEUS identified potential inhibi-
tors of PAD4 from the database, more accurate analysis
was carried out using AutoDock for flexible ligand dock-
ing. The compounds were ranked again after docking
using AutoDock according to their predicted binding
affinity to PAD4.
In structure-based ligand screening, one must be care-
ful in choosing the most suitable protein structure from
the Protein Data Bank, particularly if one is working with
a protein target represented in multiple crystal structures.
It is well known that many proteins undergo conforma-
tional changes upon binding to ligands, cofactors, or
metal ions. These structural rearrangements may open
the binding pocket of the protein, often referred to as a
“closed” to “open” transition. Choosing a representation
of the protein in its “open” conformation may cause
misidentification of active ligands as a result of the inabil-
ity of the ligand to bind in the “closed” form of the bind-
ing pocket. After carefully analyzing several crystal
structures of PAD4 available in the Protein Data Bank,
the crystal structure of PAD4 in complex with Ca2+ and
benzoyl-L-arginine amide (BAA) (PDB:1WDA, Figure 2)
was chosen for our structure-based screening and dock-
ing. This structure represents the highest resolution
structure available at the time of writing. There are five
Ca2+ binding sites identified in the structure of PAD4
with the protein undergoing massive structural rearran-
gements upon binding to Ca2+ [27]. The attachment of
these cations induces conformational changes that open
a cleft in the PAD4 active site, subsequently allowing
ligand to enter the active site. However, 1WDA structure
has a Cys645Ala mutation. Therefore, we performed an
in-silico Ala645Cys mutation on the 1WDA structure
using Coot 8.04.3, matching the human PAD4 sequence.
The Coot program allows amino acid mutation with con-
sideration given to side-chain rotamer positions.
The active site of PAD4 has been studied by many
research groups [28-32] with the goal of understanding
the catalytic mechanism of the enzyme. Knuckley et al.,
[33] suggested that PAD4 utilizes a reverse protonation
mechanism. They claimed that Cys645 and His471 are
essential for substrate binding. Inhibitors proposed by
Luo et al. [34,35] were designed to block Cys645 from
binding with the substrate.
Potential inhibitors obtained from LIDAEUS were not
targeted to any specific amino acid of the active site. Site
points generated in the active site are used to define ener-
getically favourable locations for specific atom types, tak-
ing into account contributions from van der Waals,
hydrophobic and hydrogen bonding interactions. Potential
inhibitors were indentified using LIDAEUS as a course
grained (rigid protein-rigid ligand) docking technique, fol-
lowed by a more rigorous treatment with AutoDock.
Inhibitory activity of hits
After potential in-silico hit identification, a quick experi-
mental screen was carried out. One of the criteria for a
drug is that it has to be soluble in aqueous medium. Drugs
with poor aqueous solubility are likely to have absorption
problems since the flux of drugs across the intestinal
membrane is proportional to concentration gradients
between the intestine lumen and blood [36]. From the top
100 compounds obtained after molecular docking, 22 aqu-
eous soluble compounds were selected for quick screen-
ing. To perform quick screening, an inhibition assay was
carried out and the activity of PAD4 after inhibition was
compared with a negative control. Compound concentra-
tion was fixed at 100 μM and the percentage of PAD4
activity remaining after adding inhibitor calculated.
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Additional File 1: Table S1 shows the IDs, rankings, struc-
tures, and binding affinities of the compounds tested in
this work.
A known PAD4 inhibitor was chosen for this work as
a positive control. A disease modifying anti rheumatic
drug, streptomycin, with the reported half maximal inhi-
bitory concentration (IC50) value of 1.8 ± 0.3 mM
against PAD4 [33] was selected for this purpose. Com-
pounds that significantly reduced PAD4 activity were
considered as potential inhibitors. Out of 22 com-
pounds, there were three compounds (compound 9, 10,
and 59) that showed significant inhibition of PAD4
(Figure 3), reducing PAD4 activity by more than 5% at
100 μM (significant difference; p < 0.1). The binding affi-
nities of compounds 9, 10, and 59 with PAD4 as calcu-
lated by AutoDock were -7.49, -7.27, and -6.00 kcal/mol,
respectively. There is little molecular similarity present in
the three top inhibitors, apart from the presence of oxy-
gen-containing ring. These three compounds were
further studied for their potency in inhibiting PAD4
enzymatic activity. IC50 values for the compounds were
determined by inhibition assays using various inhibitor
concentrations. The data obtained were fitted into a stan-
dard IC50 equation in the Grafit program [37] to calculate
relative IC50 values. Figure 4 shows the concentration -
response curve of the compounds. IC50 values calculated
by the program for compounds 9, 10, and 59 were 2.50,
0.46, and 1.54 mM, respectively. The absolute IC50,
which is the concentration of the inhibitor that brings
the activity of the enzyme down to 50%, were estimated
from graphs. The estimated absolute IC50 values for
compound 9, 10, and 59 were 2.9, 1.6, and 1.5 mM,
respectively.
Molecular docking analysis of hits
Compound 9 with an IC50 of 2.50 mM forms five hydrogen
bonds and four hydrophobic interactions with residues in
the binding site of PAD4 (Figure 5A). Two hydrogen
Figure 2 Structure of protein arginine deiminase type 4 [PDB:1WDA]. (a) Ribbon representation of PAD4; a-helix is illustrated in red and b-
sheet is illustrated in yellow. (b) Surface representation of PAD4 with benzoyl-l-arginine amide (BAA) inside the enzyme binding site.
Figure 3 Percentage of remaining activity of PAD4 in the presence of 22 compounds. Twenty two compounds were selected from virtual
screening results based on their solubility and AutoDock binding affinities. The concentration of each compounds was 100 μM.
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bonds are formed between the side chain carboxylic acid of
Asp473 and the side chain thiol of Cys645 with the hydro-
xyl group of compound 9. Two hydrogen bonds are also
formed between the backbone oxygen of His640 and the
side chain carboxylic acid of Glu474 with the amine group
of the inhibitor. Another hydrogen bond is formed
between the side chain amine of Asn585 with an oxygen
atom in the ether ring of compound 9. Compound 10,
which shows strongest binding to PAD4 as indicated by its
low IC50 value forms eight hydrogen bonds with residues
in the binding site (Figure 5B). Four hydrogen bonds are
formed between the side chain carboxylic acid of Asp473,
the side chain thiol of Cys645, and side chain amine of
Asn588 with two hydroxyl groups in compound 10. Two
hydrogen bonds are formed between the backbone oxygen
of His640 and the side chain carboxylic acid of Glu474
with amine in the thioazolidine ring of the inhibitor.
Another hydrogen bond is also formed between sulfur
Figure 4 Concentration - respond curves of compound 9 (a), 10 (b) and 59 (c) against PAD4.
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atom of the thioazolidine ring with the side chain amine of
Asn585. One hydrogen bond is formed between the back-
bone amine of Ala581 with oxygen in the furan ring of
compound 10. As for compound 59, there are three hydro-
gen bonds formed with residues in the binding pocket, i.e.
one interaction between the backbone amine of Val469
and the nitro group of the inhibitor, another hydrogen
bond between the same nitro group with the side chain
carboxylic acid of Glu474, and one hydrogen bond between
the backbone oxygen of His637 and hydroxyl group of the
compound (Figure 5C). There are five conserved residues
that bind to compounds 9 and 10 (Asp473, Glu474,
Asn585, His640, and Cys645) indicating that both com-
pounds bind to the same location. In contrary, compound
59 binds to different residues indicating that this com-
pound sits in different part of the PAD4 binding site.
Our docking results show that all three compounds
have different predicted binding modes than that of
BAA (PAD4 substrate) and F-amidine, the most potent
irreversible PAD4 inhibitor ever reported [34]. PoseView
analysis shows that BAA interacts with six residues in
the binding site of PAD4 and only three of them were
predicted to interact with the compounds reported in
this work, i.e., Asp473, His640, and Cys645. The same
analysis shows that F-amidine interacts with five resi-
dues in the binding site of PAD4, only two of them
interacting with compounds in this work, i.e., Val469
and Cys645 (Figure 6). The difference in binding orien-
tation between BAA and F-amidine compared to three
compounds that we discovered could be due to the
uniqueness of the PAD4 binding pocket, discussed
below (Figure 7).
Figure 5 Binding conformations of compounds 9 (a), 10 (b), and 59 (c) inside the PAD4 binding pocket. Hydrogen bonds are drawn as
dashed lines, hydrophobic interactions are drawn as green lines. Residues that form hydrogen bond and hydrophobic interactions with each
compound are shown. Figures were plotted using PoseView.
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Discussion
To date, the therapies available for RA treatment are
merely treating its symptoms [34]. The discovery of
anticitrullinated protein autoantibody as a specific auto-
antibody to RA has led to the discovery of PAD4 as a
new therapeutic target for RA. It is hoped that inhibitors
of PAD4 can treat the underlying cause of the disease.
The catalytic mechanism of PAD4 was investigated [33]
in order to identify important features that could be
exploited for inhibitor development.
The discovery of drugs can be accelerated by the use of
computational methods in lead identification and optimiza-
tion. High-Throughput Screening (HTS) is a conventional
experimental method which identifies leads by carrying out
individual biochemical assays with more than millions
compounds. It is a good method for the identification of
leads but is costly and time consuming. This leads to the
integration of another computational methodology, namely
virtual high throughput screening (vHTS) [38]. vHTS is a
computational screening method widely used to screen
in-silico collections of compounds and predict binding affi-
nities of library compounds to the target receptor. vHTS
aims to operate on millions of compounds in a short per-
iod of time. HTS and vHTS are complementary methods;
HTS confirms the accuracy of vHTS predictions.
vHTS has been performed in many projects searching
for therapeutics - for example, nuclear hormone receptor
antagonists for cancer, diabetes and neurological diseases
[39], CK2 inhibitors as antitumor agents [40], 17b-hydro-
xysteroid dehyrogenase type 1 inhibitors for breast cancer
[41], and tyrosine phosphorylation regulated kinase 1A
inhibitors for Down’s syndrome [42]. LIDAEUS, the
structure-based vHTS program utilized in this work has
been previously employed in drug discovery efforts
searching for CDK inhibitors (targeting cancer cells) [21],
cyclophilins inhibitors for HIV infection [43], and NS5
methyltransferase for dengue fever [26].
This work is the first report on the usage of structure-
based virtual screening to discover novel inhibitors against
PAD4. In this work, instead of synthesizing new com-
pounds, we searched for inhibitors of PAD4 using the
LIDAEUS program. The “drug universe” (including all the
possible drug-like molecules) consists of 1062 molecules
[44]. It is believed that potential drugs can be identified
from the large “drug universe” without synthesizing more
new compounds. The hit rate in our work is 14%, which is
similar to previous work performed using LIDAEUS [45]
followed by more rigorous docking treatments. The results
obtained from vHTS using LIDAEUS were not in agree-
ment with the experimental screening, where the top vir-
tually screened compounds do not always turn out as hits
after enzymatic screening. There is a lack of correlation
between AutoDock binding affinity and the inhibitory
activity of the compounds (Figure 8). We discovered that
the most active hits were compounds 9, 10, and 59, with
IC50 values in milimolar range. The non-existence of a
straightforward correlation between high ranked com-
pounds in vHTS and their inhibitory activity, and the
weak binding of three compounds discovered through this
work are somewhat disappointing. Nevertheless, the
Figure 6 Binding conformations of benzoyl-L-arginine amide or BAA (PDB:2DW5] (a) and F-amidine [PDB:1WDA] (b) inside the PAD4
binding pocket. Hydrogen bonds are drawn as dashed lines, hydrophobic interactions are drawn as green lines. Residues that form hydrogen
bond and hydrophobic interactions with each compound are shown. Figures were plotted using PoseView.
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findings of this work may provide useful scaffolds for
designing more potent inhibitors against PAD4 and most
importantly provide insights into structure-based virtual
screening for similar protein targets. The rationale behind
disagreement between our vHTS and inhibitory assay
results, and weak binding of three inhibitors identified
using LIDAEUS could be attributed to limitations in our
methodology as well as unique structural features of the
PAD4 binding site hindering structure-based ligand search
strategies. First, LIDAEUS omits water molecules in its
screening process, and this may contribute to ligand-water
interactions being ignored. It is known that water
Figure 7 Binding pocket of PAD4 with two accessible tunnels labeled as “front door” and “back door” [PDB:1WDA]. Benzoyl-L-arginine
amide (BAE) is seen occupying the “main door” with the amino acid residues that interact with BAE are marked yellow. The “back door” is
visible with the residues that interact with compounds 9, 10, and 59 are marked red.
Figure 8 Correlation plot between AutoDock binding affinity and the inhibitory activity of the compounds.
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molecules play an important role in protein-ligand bind-
ing; however, the difficulties in exact positioning of explicit
water molecules around proteins result in most existing
docking and scoring functions using crude approximations
for reasons of speed and efficiency. Second, the outstand-
ing issue of protein flexibility in the docking protocol may
play a significant role in predicting properties of hit com-
pounds [38]. LIDAEUS does not take protein flexibility
into account.
From a protein structure point of view, the shape of
the PAD4 binding pocket makes structure-based ligand
screening somewhat difficult. The active site of PAD4 is
characterized by its U-shape and has two doors: the
“front door” that is used by PAD4 substrates and ami-
dine inhibitors to bind and affect the catalytic activity of
the enzyme, and the “back door” that provides another
access into the critical residues in the active site of
PAD4 (Figure 7). Our AutoDock results for compounds
9, 10, and 59 show that these compounds bind to the
“back door” of the U-shaped binding pocket of PAD4
down at the bottom of the pocket without significantly
blocking the “front door”, which causes the PAD4 active
site to remain open. This could be the reason why
strong binding affinities predicted for the three com-
pounds are not translated into actual inhibitory activity.
However, it is interesting to see that several compounds
from our screening efforts with AutoDock with predicted
binding poses at the “front door” of PAD4 did not pro-
duce any inhibitory activity in our assay (Figure 9).
A similar scenario happens with streptomycin, a weak
PAD4 inhibitor that was postulated to bind into PAD4
active site, presumably at the “front door”, based on
kinetic study data [46]. Despite the proposed mechanism
of PAD4 catalysis that is well accepted and supported by
experimental results, a comprehensive understanding on
how PAD4 is inhibited is still far from complete.
Nevertheless, we have identified several compounds as
potential therapeutics for RA. By comparing the com-
pounds with reported inhibitors [34,35,46-49], there is
no similarity between reported inhibitor structures and
potential inhibitors discovered in this work. Luo et al.
[34,35] proposed amidine inhibitors containing halogens
capable of forming a stable thiother adduct between the
inhibitor and Cys645, which has been suggested as an
essential amino acid in the citrullination process [33].
Initially, it was thought that ideal PAD4 inhibitors must
be able to penetrate deeply into the active site of PAD4
where Cys645 is located, this scenario is only possible if
the inhibitors mimic the structure of an arginine side
chain. Amidine derivatives were discovered by mimick-
ing the structure of benzoylarginine amide, an arginine-
containing PAD4 substrate. However, later findings
show that there are compounds without any similarity
with arginine show significant inhibition against PAD4
Figure 9 Binding pose of compound 16 (SPH1-109-603) inside the PAD4 binding pocket. The binding conformation of this compound is
seen occupying both “front door” and “back door”. Hypothetically, this compound was thought having the highest inhibitory activity. However,
quick screening result proved that the compound does not have any inhibitory activity against PAD4.
Teo et al. BMC Bioinformatics 2012, 13(Suppl 17):S4
http://www.biomedcentral.com/1471-2105/13/S17/S4
Page 9 of 13
in micromolar scale, such as streptomycin, minocycline,
chlortetracycline, and streptonigrin that shows multiple
fold higher inhibitory activity against PAD4 than that of
amidine compounds [46,47]. These facts suggest that
potential PAD4 inhibitors may be identified by the pre-
sence of a warhead that protrudes into the deep binding
site of PAD4 and subsequently forms a stable bond with
Cys645, thus completely blocking the action of PAD4;
however, that is not an absolute prerequisite for a PAD4
inhibitor as has been show by the efficacy of larger
molecules such as streptomycin, minocycline, chlortetra-
cycline, and streptonigrin in inhibiting PAD4 activity.
In this work we found few compounds that inhibit the
activity of PAD4. None of these compounds mimic the
structure of arginine or previously discovered PAD4 inhi-
bitors. Compound 9 and 59 contain five-membered rings
while compound 10 contains furan (a cyclic ether) and
thiazolidine rings. Furan rings are found in many natural
products and synthetic drug molecules [50]. Zeni et al.,
[51] synthesized a series of compounds containing furan
rings and studied their anti-inflammatory behavior. They
tested the compounds using the carrageenin-induced paw
edema method, and discovered that several compounds
exhibited greater potency than classical anti-inflammatory
agents in inhibiting paw edema formation. A furan-
containing compound synthesized by Closse et al. [52],
5-chloro-6-cyclohexyl-2,3-dihydrobenzofuran-2-one, was
more active than the reference compounds, indomethacin
and diclofenac in inhibiting the acute inflammation and
the adjuvant-induced arthritis. Wakimoto et al., [53] pro-
posed that furan fatty acids could be potential antioxidants
which may prevent chronic inflammatory diseases.
The thioazolidine ring, which is present in compound
10, possesses a wide range of promising biological activ-
ities. Thiazolidine has shown its importance as an antimi-
crobial, anti-inflammatory, anticonvulsant, antimalarial,
analgesic, anti-HIV and anticancer agent [54]. Thiazolidine
dione was identified as a compound which has high
potency in suppressing chronic inflammation and joint
destruction [55]. The compound has been studied for its
antiarthritic activity against rat adjuvant arthritis which is
a chronic T cell-dependent autoimmune disease with
many similarities to rheumatoid arthritis and exhibited
activity at daily oral doses between 0.01 and 1 mg/kg [55].
Ma et al., [56] synthesized a series of thiazolidene diones
and examined the antiarthritic potency of the most active
compound with adjuvant induced arthritis. Rats treated
with thiazolidine compound did not develop severe arthri-
tis after adjuvant injection, loss of body weight was also
reduced significantly. This indicated that the compound
exhibited potential immunomodulating activity.
The IC50 values of the inhibitors discovered in this
work were lower compared to existing drugs for RA
treatment. The most common recently used drug for
RA treatment is methotrexate with an IC50 value of
more than 10 mM [46]. Paclitaxel showed inhibition to
PAD isolated from bovine brain with IC50 value of
approximately 5 mM. Besides methotrexate and pacli-
taxel, other DMARDs such as sulfamethoxazole, tri-
methoprim, and 5-aminosalicylic acid were also
investigated for their potency in inhibiting PAD4 [46].
Most of the DMARDs have high IC50 values. Among
the tested DMARDs, chlortetracycline showed the best
inhibition of PAD4 (IC50 = 100 μM). Although the three
compounds discovered in this work have higher IC50
compared to chlortetracycline and amidine inhibitors,
LIDAEUS has discovered a new class of compound that
are able to inhibit PAD4.
Conclusions
We have discovered three inhibitory compounds against
PAD4 through structure-based virtual screening using
LIDAEUS. These compounds show IC50 values between
1.54 to 2.50 mM. The compounds have thioazolidine and
cyclic ether groups in their structures, which may suggest
the importance of those groups in inhibiting the enzymatic
activity of PAD4. The compounds are commercially avail-
able and can be utilized as scaffold to design more potent
PAD4 inhibitors. The new class of PAD4 inhibitors discov-
ered during the course of this work provide a starting
point not only for medicinal chemists, but for the future
in-silico work based on molecular similarity and scaffold
hopping. With binding modes predictable by virtual
screening, ligand-based virtual screening techniques feed-
ing into structure-based techniques offer the ability to
explore structure-activity relationship (SAR) using com-
mercially available small molecules, greatly focusing med-
icinal chemistry efforts.
Methods
Expression and purification of PAD4
PAD4 cDNA was purchased from Genecopoeia (Rockville,
MD, USA) and amplified using PCR with primers
designed according to the gene sequence (accession num-
ber: NM_012387). The cDNA of PAD4 consisted of 1992
base pairs nucleotides. The band size of the amplified gene
was checked by agarose gel electrophoresis and the gene
was purified by gel extraction using GeneAll DNA Purifi-
cation Kit (GeneAll, Seoul, South Korea). The purified
cDNA of PAD4 was then digested with EcoRV and
Bpu1102I (Fermentas, Vilnius, Lithuania) and cloned into
vector pET32b (Novagen, Madison, WI, USA). The pre-
sence of the insert in the vector was confirmed by double
digestion with restriction enzymes and DNA sequencing.
After that, the plasmid that produced correct band sizes
after double digestion and with correct DNA sequence
was transformed into E. coli BL21(DE3)pLysS (Invitrogen,
Carlsbad, CA, USA) for protein expression. E.coli was
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grown in Studier media [23]. The seed culture was pre-
pared in MDG media, then inoculated at a 1:1000 dilution
into ZYM-5052 media. The bacteria were grown for 5 to
6 hours at 37°C under agitation (220 rpm) until the culture
appeared turbid, the temperature was then dropped to
20°C and the culture allowed to grow overnight. The cells
were harvested by centrifugation at 10000 rpm for 10 min-
utes, then resuspended in lysis buffer (100 mM Tris pH
7.2, 500 mM NaCl, 30 mM imidazole, and 1 mg/ml lyso-
zyme) and lysed by sonication. The cell debris were
removed by centrifugation. The supernatant was passed
through a Ni Sepharose™ 6 Fast Flow affinity column (GE
Healthcare, Uppsala, Sweden) for purification. The column
was washed with a binding buffer (100 mM Tris pH 7.2,
500 mM NaCl and 30 mM imidazole) and the His-tagged
PAD4 was eluted with an elution buffer (100 mM Tris pH
7.2, 500 mM NaCl and 500 mM imidazole). The presence
of the protein in specific fractions was detected by SDS-
PAGE analysis. Fractions containing the protein were
pooled and stored at 4°C.
Computer-aided virtual screening
A web- based high-throughput virtual screening pro-
gram, LIDAEUS http://opus.bch.ed.ac.uk/lidaeus/index.
php[21] was utilized in searching for potential inhibitors
of PAD4. The three-dimensional structure of PAD4 was
retrieved from the Protein Data Bank [PDB:1WDA]. The
structure was prepared for structure-based virtual screen-
ing and molecular docking by removing all water mole-
cules and Ala645 was mutated to Cys to match the
human sequence using the Coot 8.04.3 program. The
mutated PAD4 structure was uploaded to the LIDAEUS
web service where site points were generated defining the
search space to be explored within the active site of the
protein. Around 1 million compounds were screened by
fitting to the generated site points and subsequent scor-
ing against pre-generated energy maps, accounting for
van der Waals, hydrophobic and hydrogen bonding inter-
actions. The top ranked top 500 compounds predicted by
LIDAEUS were redocked using the more computationally
expensive and exhaustive virtual screening program




The assay was carried out based on the protocol sug-
gested by Takahara et al., with some modifications [24].
The reaction buffer containing 100 mM Tris (pH 7.2),
10 mM calcium chloride, 10 mM DL-dithiothreitol and
0.2 ml of the enzyme solution was incubated at 37°C for
2 minutes. The reaction was started by adding the sub-
strate, 10 mM N-a-benzoylarginine ethyl ester (BAEE)
and the reaction mixture was then incubated at 37°C for
30 minutes. The enzymatic reaction was terminated by
adding 60% (w/v) perchloric acid. The reaction mixture
was centrifuged to remove aggregated PAD4 after termi-
nation. Half of the reaction mixture was used for the
colorimetric determination of citrulline. For color devel-
opment, Redox Reagent prepared by ferrous ammonium
sulfate hexahydrate and ammonium iron (III) sulfate
dodecahydrate in 1 N H2SO4 was added to the reaction
mixture, then boiled for 10 minutes. After cooling down
to room temperature, theacid mixture (phosphoric acid,
sulfuric acid and deionized water) and 12.5 mM of 2,3-
butanedione monoxime solution was added. It was
boiled for 20 minutes then cooled. The absorbance at
490 nm was measured and compared to a citrulline
standard curve to determine the concentration of citrul-
line produced during the course of the reaction. The
amount of protein was determined by the Bradford
method with bovine serum albumin (BSA) as standard
[58].
PAD4 inhibition assay - quick screening
The reaction buffer containing 100 mM Tris (pH 7.2),
10 mM calcium chloride, 10 mM DL-dithiothreitol,
100 μM inhibitor and 0.06 μM enzyme solution was
incubated at 37°C for 15 minutes. 1 mM BAEE was
added to start the enzymatic reaction and the reaction
mixture was incubated at 37°C for 15 minutes. The
enzymatic reaction was terminated by adding 60% (w/v)
perchloric acid. Citrulline produced was determined
spectrometrically as described above.
IC50 studies
IC50 values of compounds that showed significant inhi-
bition against PAD4 were determined by pre-incubating
various concentrations of the inhibitors in the reaction
buffer as described above. The enzymatic reaction was
started by adding 1 mM BAEE and the reaction was
allowed to occur for 15 minutes. The reaction was then
terminated and the amount of citrulline produced deter-
mined as described above. IC50 values were determined
by fitting the data to standard IC50 equations in the
Grafit program [37].
Additional material
Additional file 1: Table S1 Table S1: Compound ID, rank, structure,
and binding affinity of 22 compounds tested for their inhibitory
activity against PAD4. (*.doc).
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